Although one drawback of COX-2 inhibitors such as rofecoxib and celecoxib was reported as the elevation of myocardial infarction and stroke risk, Meloxicam has been reported to be safer in that respect [60]. The gene discussed is PTGS2; the disease is stroke disorder.